Cardiol Therapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions CAD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Cardiol Therapeutics Inc. (CRDL) - Annual data in millions CAD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2018
Operating Activities
Net Income-36.68-28.13-30.93-31.64-20.64-15.89
Depreciation & Amortization0.230.250.220.220.230.09
Stock Based Compensation14.284.175.548.502.810.00
Change in Working Capital-0.93-0.555.750.088.32-5.20
Change in Accounts Receivable0.040.07-0.14-0.060.010.00
Change in Inventory0.000.000.000.025.850.00
Change in Accounts Payable-1.06-1.294.472.391.830.00
Change in Other Working Capital0.090.681.424.130.640.00
Other Operating Activities-2.10-0.93-9.154.210.070.57
Net Cash from Operating Activities-25.06-25.18-27.22-23.55-9.13-10.89
Investing Activities
Capital Expenditures-0.02-0.06-0.070.01-0.04-0.01
Net Cash from Investing Activities-0.02-0.06-0.07-0.01-0.04-0.01
Financing Activities
Debt Repayment-0.04-0.06-0.05-0.050.000.00
Common Stock Issued21.530.000.0084.0817.4314.23
Other Financing Activities-2.650.000.00-5.24-1.09-1.02
Net Cash from Financing Activities18.84-0.06-0.0593.4416.3025.28
Summary
Effect of Forex Changes on Cash1.890.762.92-0.010.000.00
Net Change in Cash-4.35-24.54-24.4369.877.0714.37
Cash at Beginning of Period34.9359.4783.9014.030.002.36
Cash at End of Period30.5834.9359.4783.900.0016.73
Free Cash Flow-25.08-25.24-27.30-23.55-9.17-10.91